ARS Pharmaceuticals Inc (NASDAQ:SPRY) has a beta value of 0.89 and has seen 1.61 million shares traded in the last trading session. The company, currently valued at $1.53B, closed the last trade at $15.20 per share which meant it lost -$0.06 on the day or -0.39% during that session. The SPRY stock price is -12.37% off its 52-week high price of $17.08 and 77.76% above the 52-week low of $3.38. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.88 million shares traded. The 3-month trading volume is 1.16 million shares.
The consensus among analysts is that ARS Pharmaceuticals Inc (SPRY) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Sporting -0.39% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SPRY stock price touched $15.20 or saw a rise of 6.52%. Year-to-date, ARS Pharmaceuticals Inc shares have moved 177.37%, while the 5-day performance has seen it change 1.40%. Over the past 30 days, the shares of ARS Pharmaceuticals Inc (NASDAQ:SPRY) have changed 7.12%. Short interest in the company has seen 11.92 million shares shorted with days to cover at 12.65.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 30.91% from current levels. The projected low price target is $18.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -97.37% off the targeted high while a plunge would see the stock gain -18.42% from current levels.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Figures show that ARS Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 60.85% over the past 6 months, with this year growth rate of -15.79%, compared to 18.30% for the industry. Revenue growth from the last financial year stood is estimated to be 16,933.30%.
4 analysts offering their estimates for the company have set an average revenue estimate of 560k for the current quarter. 4 have an estimated revenue figure of 4.05M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.44% over the past 5 years.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Insiders own 23.21% of the company shares, while shares held by institutions stand at 66.12% with a share float percentage of 86.11%. Investors are also buoyed by the number of investors in a company, with ARS Pharmaceuticals Inc having a total of 180.0 institutions that hold shares in the company.
